Response adaptive designs are used in phase III clinical trial for skewing the allocation pattern towards the better treatments. We use optimum design theory to derive adaptive designs when the responses are normally distributed. The performance of the designs is studied with respect to the loss and the proportion of allocation to different treatments. The adaptive design does not affect inference.
No takes yet. Share an insight, caveat, or question.
Atkinson et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: